SLS · SELLAS Life Sciences Group, Inc.
Market Cap
$2.80B
Shares
201.95M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$0
-100%
FY2023
Net Income
-$26.86M
+13%
FY2025
Gross Margin
90%
-7.4pp
FY2022
Operating Margin
-4195%
-3862.2pp
FY2022
Diluted EPS
-$0.25
+50%
FY2025
Operating Cash Flow
-$28.39M
+19.8%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | $0 | $1M | $7.6M | $1.9M | $0 | — | — | — | — | $9.32M | $2.49M | $0 | $0 | — | |
| $422K | — | — | $525K | $317K | $6000 | $26K | $118K | -$266K | -$462K | -$1.17M | — | — | — | — | — | — | |
| $0 | $0 | $0 | $0 | $100K | $200K | $0 | — | — | — | — | — | $1.4M | $520K | $0 | $0 | — | |
| — | — | — | $0 | $900K | $7.4M | $1.9M | — | — | — | — | — | $7.92M | $1.97M | $0 | $0 | — | |
| — | — | — | — | 90% | 97.37% | 100% | — | — | — | — | — | 84.94% | 79.09% | — | — | — | |
| $20.35M | $16.02M | $19.1M | $24.01M | $20.27M | $15.67M | $9.28M | $7.29M | $8.77M | $6.07M | $11.4M | $23.61M | $27.67M | $20.42M | $14.61M | $3.85M | $7.87M | |
| $4.36M | — | — | — | — | — | — | — | — | $900K | — | — | — | — | $6.59M | $8.64M | $8.75M | |
| — | $12.25M | $12.42M | $13.86M | $12.58M | $11.32M | $9.6M | $9.92M | $12.77M | $15.09M | $4.59M | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | $0 | $1.88M | — | — | $440K | $131K | — | — | — | |
| -$16K | — | — | — | — | — | — | — | — | — | $3000 | $107K | $86K | $286K | $49K | $163K | $172K | |
| — | — | — | — | — | — | — | — | — | — | $31.87M | $34.22M | $43.9M | $28.49M | $21.2M | $12.49M | $16.63M | |
| $35.22M | $28.27M | $31.51M | $37.87M | $42.95M | $32.89M | $18.88M | $20.04M | $31.09M | $23.04M | — | — | — | — | — | — | — | |
| -$35.22M | -$28.27M | -$31.51M | -$37.87M | -$41.95M | -$25.29M | -$16.98M | -$20.04M | — | -$23.04M | -$15.99M | -$34.22M | -$43.9M | -$28.49M | -$21.2M | -$12.49M | — | |
| — | — | — | — | -4195% | -332.82% | -893.79% | — | — | — | — | — | -471.08% | -1145.52% | — | — | — | |
| -$5.73M | — | — | — | — | — | — | — | — | — | -$15.99M | -$34.11M | -$43.81M | -$28.2M | -$21.15M | -$12.32M | — | |
| $2.76M | $1.41M | $632K | $529K | $649K | $4.36M | $208K | -$19.37M | -$29.05M | -$23.5M | $21.01M | -$4.37M | $15.62M | -$41.79M | -$13.18M | $9.08M | $4.63M | |
| — | -$26.86M | -$30.88M | -$37.34M | -$41.3M | -$20.94M | -$16.77M | -$19.37M | -$29.05M | -$23.5M | -$17.68M | -$38.59M | -$28.28M | -$70.28M | -$34.38M | -$3.41M | -$11.99M | |
| — | $0 | $0 | $0 | $0 | -$237K | -$17K | -$81K | -$1.38M | $253K | $1000 | $365K | $0 | $1.05M | -$1.05M | — | — | |
| -$32.46M | -$26.86M | -$30.88M | -$37.34M | -$41.3M | -$20.7M | -$16.76M | -$19.29M | -$27.67M | -$23.75M | -$17.68M | -$63.9M | -$36.61M | -$76.68M | -$34.97M | -$11.49M | -$11.99M | |
| — | — | — | — | -4130.1% | -272.36% | -881.95% | — | — | — | — | — | -392.81% | -3083.15% | — | — | — | |
| — | — | — | — | — | -$20.7M | -$16.84M | -$27.95M | -$41.25M | -$24.43M | -$17.68M | — | — | — | — | — | — | |
| USD/shares | -$0.21 | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | -$0.21 | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 | -$2.11 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 109.05M | 61.2M | 27.78M | 19.4M | 15.48M | 7.98M | 2.56M | 261.54K | 2.34M | 947.4K | 7.76M | 5.97M | 90.18M | 62.48M | 36.33M | — |
| shares | — | 109.05M | 61.2M | 27.78M | 19.4M | 15.48M | 7.98M | 2.56M | 261.54K | 2.34M | 947.4K | 7.76M | 5.97M | 90.18M | 62.48M | 36.33M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2019: $3.85M in buybacks, $487K in dividends.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 8.28×
EV/EBIT
—
Peer median 17.01×
P/E (TTM)
—
Peer median 18.50×
Peer medians compare against the 235 similar-size Biotechnology companies (of 516 listed).
Key facts
CIK
1390478
CUSIP
81642T209
13F (30d)
121 filings
121 filers
Visit website
Investor relations